Abstract
The human genome encodes 40 voltage-gated K + channels (K V), which are involved in diverse physiological processes ranging from repolarization of neuronal and cardiac action potentials, to regulating Ca 2+ signalling and cell volume, to driving cellular proliferation and migration. KV channels offer tremendous opportunities for the development of new drugs to treat cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders. This Review discusses pharmacological strategies for targeting KV channels with venom peptides, antibodies and small molecules, and highlights recent progress in the preclinical and clinical development of drugs targeting the K V 1 subfamily, the KV 7 subfamily (also known as KCNQ), KV 10.1 (also known as EAG1 and KCNH1) and KV 11.1 (also known as HERG and KCNH2) channels.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 982-1001 |
| Number of pages | 20 |
| Journal | Nature Reviews Drug Discovery |
| Volume | 8 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2009 |
Fingerprint
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
- Medicine(all)
Cite this
Voltage-gated potassium channels as therapeutic targets. / Wulff, Heike; Castle, Neil A.; Pardo, Luis A.
In: Nature Reviews Drug Discovery, Vol. 8, No. 12, 12.2009, p. 982-1001.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Voltage-gated potassium channels as therapeutic targets
AU - Wulff, Heike
AU - Castle, Neil A.
AU - Pardo, Luis A.
PY - 2009/12
Y1 - 2009/12
N2 - The human genome encodes 40 voltage-gated K + channels (K V), which are involved in diverse physiological processes ranging from repolarization of neuronal and cardiac action potentials, to regulating Ca 2+ signalling and cell volume, to driving cellular proliferation and migration. KV channels offer tremendous opportunities for the development of new drugs to treat cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders. This Review discusses pharmacological strategies for targeting KV channels with venom peptides, antibodies and small molecules, and highlights recent progress in the preclinical and clinical development of drugs targeting the K V 1 subfamily, the KV 7 subfamily (also known as KCNQ), KV 10.1 (also known as EAG1 and KCNH1) and KV 11.1 (also known as HERG and KCNH2) channels.
AB - The human genome encodes 40 voltage-gated K + channels (K V), which are involved in diverse physiological processes ranging from repolarization of neuronal and cardiac action potentials, to regulating Ca 2+ signalling and cell volume, to driving cellular proliferation and migration. KV channels offer tremendous opportunities for the development of new drugs to treat cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders. This Review discusses pharmacological strategies for targeting KV channels with venom peptides, antibodies and small molecules, and highlights recent progress in the preclinical and clinical development of drugs targeting the K V 1 subfamily, the KV 7 subfamily (also known as KCNQ), KV 10.1 (also known as EAG1 and KCNH1) and KV 11.1 (also known as HERG and KCNH2) channels.
UR - http://www.scopus.com/inward/record.url?scp=73449119314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73449119314&partnerID=8YFLogxK
U2 - 10.1038/nrd2983
DO - 10.1038/nrd2983
M3 - Article
C2 - 19949402
AN - SCOPUS:73449119314
VL - 8
SP - 982
EP - 1001
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
SN - 1474-1776
IS - 12
ER -